GSK plc's drug Linerixibat for cholestatic pruritus has been accepted for priority review in China as of February 26, 2026, based on positive phase III trial results showing significant improvement in patients. Approximately 280,000 people in China suffer from this rare condition, affecting up to 89% of those with primary biliary cholangitis.